Profitability Ratios
| Ratio |
Value |
| GP Margin |
100.0% |
| EBIT Margin |
-22.5% |
| EBITDA Margin |
-20.7% |
| Operating Margin |
-29.3% |
| Pretax Margin |
-22.5% |
| Cont. Ops Margin |
-22.8% |
| Net Margin |
-22.8% |
| Bottom Line Margin |
-22.8% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
3.09 |
| Quick Ratio |
3.09 |
| Solvency Ratio |
-0.304 |
| Cash Ratio |
0.27 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.20 |
| Forward PEG |
0.20 |
| Price/Book |
5.93 |
| Price/Sales |
7.71 |
| Price/FCF |
-7.75 |
| Price/Op Cash Flow |
-7.77 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.0280 |
| Debt/Equity |
0.0428 |
| Debt/Capital |
0.0411 |
| Long-Term Debt/Capital |
0.0000 |
| Financial Leverage |
1.53 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.28 |
| Operating Cash Flow Ratio |
-1.622 |
| Operating Cash Flow/Sales |
-99.2% |
| Free Cash Flow/Operating Cash Flow |
100.3% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-3.77 |
| Interest Coverage |
0.0000 |
| Short-Term Operating Cash Flow Coverage |
-17.83 |
| Operating Cash Flow Coverage |
-17.83 |
| Capital Expenditure Coverage |
-343.58 |
| Dividend + Capital Expenditure Coverage |
-343.58 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.55 |
| EPS |
-0.126 |
| Debt/Share |
0.0307 |
| Cash/Share |
0.99 |
| Book Value/Share |
0.72 |
| Tangible BV/Share |
0.71 |
| Equity/Share |
0.72 |
| Operating Cash Flow/Share |
-0.548 |
| Capital Expenditure/Share |
0.002 |
| FCF/Share |
-0.550 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.014 |
| Earnings Before Tax/EBIT |
0.766 |
| Price/Fair Value |
5.93 |
| Debt/Market Cap |
0.0072 |
| Effective Tax Rate |
-1.4% |
| Enterprise Value Multiple |
-36.76 |
CTMX - CytomX Therapeutics, Inc.